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other groups, namely sulfonylureas and thiazolidinediones, it has been declining 
each year on average by 2 % and 15 %, respectively. ConClusions: The uptake of 
incretin-based drugs since 2008 has been rapid and their utilization keeps rising, 
apparently at the expense of other drugs, namely older sulfonylurea derivatives and 
thiazolidinediones. Consequently the overall public expenditure on anti-diabetic 
therapy has been increasing.
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objeCtives: This study describes the extent of non-adherence (NA) and non-per-
sistence (NP) with Glucagon-like peptide 1 agonists (GLP-1) and oral anti-diabetic 
(OAD) therapy in T2DM patients in clinical practice in Germany. Methods: Claims 
data from a German sickness fund (AOK Plus) from 2010-2012 were used to identify 
patients with ≥ 1 diagnosis for T2DM. NA/NP were measured for patients initi-
ating new T2DM medication (no prescription of respective medication in prior 6 
months) over a minimum of 12 months. A 100% adherence to therapy was assumed 
equivalent to the drug-specific DDD (defined daily dosage). NP was defined as a 
medication gap ≥ 90 days. Adherence was calculated via medication possession 
ratios (MPR), NA was defined as MPR< 80%. Descriptive analyses with percentage 
of patients affected by NP and/or NA were conducted. Results: The NP analysis, 
included 2,490/42,891 T2DM patients initiating GLP-1s/OADs. Among GLP-1 patients, 
408/1,727/135 received twice-daily (BID; exenatide)/once-daily (OD; liraglutide)/once-
weekly (OW; exenatide) therapies. Average age for GLP-1/OAD users was 56 (SD 
10.8) /67 (SD 12.6) years. After 12 months, the percentage of patients with NP was 
36.83% (all GLP-1s), 42.65% (BID), 37.64% (OD), 27.41% (OW), and 55.87% (OAD). The 
NA analysis included 2,154/34,128 T2DM patients initiating GLP-1/OAD therapy with 
≥ 1 follow-up prescription. Average age was 56 (SD 10.6) /66 (SD 12.2) years. Average 
MPR was 88.2% (all GLP-1s), 87.8% (BID), 88.2% (OD), 95.0% (OW), and 63.2% (OAD). 
Percentage of patients affected by NA was 21.96% (all GLP-1s), 23.98% (BID), 22.00% 
(OD), 5.74% (OW), and 65.82% (OAD). ConClusions: In this German dataset, overall 
patients with T2DM had low rates of adherence and persistence despite the chronic 
nature of the disease and clinical sequelae. Higher adherence and persistence rates 
were observed with GLP-1s than with OAD medications and also with less frequently 
dosed GLP-1s.
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objeCtives: To describe the sequential treatment classes of type 2 diabetes (T2DM) 
patients initiating antidiabetic drug therapy in the Netherlands, UK (UK), Spain, 
Italy and France. To describe treatment scaling (intensification or de-intensification) 
in the overall T2DM population. Methods: Antidiabetic drug use during a 5-year 
study period (2007-2011/2008-2012) (n= 639,088) was obtained from electronic health 
care databases. A standardized analytic tool performed treatment pattern analyses 
in each database for the overall population and those initiating treatment. Oral 
monotherapy was defined as first line, oral dual therapy as second line, multiple oral 
treatments or oral in combination with an injectable as third line and injectables 
only as fourth line therapy. Results: Newly treated patients represented 33-42% 
of the overall T2DM population. Metformin monotherapy was the most common 
initial therapy (65%-87%). Around 35% (Netherlands, Italy, UK) to 45% (Spain, France) 
switched treatment within the study period. The first switch was most often to met-
formin plus a sulfonylurea (SU) in the Netherlands (47%), UK (45%), Spain (22%), Italy 
(17%), but to DPP4 inhibitors in France (15%). DPP4 inhibitor use increased during 
the study period (France 0% to 27%, UK and Spain < 1% to 9%) but remained limited 
in the Netherlands (4%) and Italy (2%). In the total cohort, first line treatment was 
most prevalent over all the years in all countries (around 50%). Intensification was 
the most common switch. Switching patients mostly stepped up or down one line 
at a time, but larger steps were also observed. Fourth line therapy was uncommon 
in France (1-2%) but accounted for about 10% in the other countries. ConClusions: 
SU remained the most common add-on treatment to metformin in most European 
countries while DPP4 inhibitor use was common in France and increased in other 
countries. Most T2DM patients are treated with oral monotherapy.
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objeCtives: Recent studies reported that seeing an endocrinologist is associated 
with better compliance with guidelines on diabetes management. This study aims 
at investigating the socioeconomic determinants of endocrinologist visits among a 
French population of diabetics. Methods: We used claim data collected for 66,508 
affiliates of a French social security provider (MGEN). Patients were aged over 18 
and treated for diabetes (types I and II). We ran logistic regressions to explore which 
factors were associated with the probability of consulting an endocrinologist. We 
controlled for patients’ socioeconomic characteristics (sex, age, income, marital 
status, activity status), type of treatment, medical care and health status. We also 
controlled for macro-level variables, such as the cost for a visit, the distance to the 
office and the medical density. Results: Women, married patients, and those work-
ing are more likely to consult an endocrinologist (p< 0.001). Age has a non-linear 
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objeCtives: Investigate how official drug safety warnings for thiazolidinediones 
(TZDs, rosiglitazone and pioglitazone) affected prescription trends for TZDs in 
Denmark and Germany and to compare the prescription patterns to data published 
for Australia, UK and the US. Methods: Identified the timing and content of all 
drug warnings for TZDs using the FDA’s and EMA’s databases. Using pharmaceutical 
claims data on all diabetes patients in Denmark and a large public health insurance 
fund in Germany, plotted the number of defined daily dosages (DDDs) per month for 
rosiglitazone and pioglitazone normalized per 1000 insurees for both countries from 
January 2007 -December 2013. Results: In Denmark rosiglitazone monotherapy 
prescriptions remained almost constant after publication of the safety warnings 
in May 2007 until drug suspension in September 2010, but declined fairly fast in 
Germany. Prescription of rosiglitazone combined with metformin declined by 1/3 
compared to their May 2007 levels in both countries. Overall market penetration of 
rosiglitazone prior to the drug warnings was ~1 DDD per day per 1000 insurees in 
Germany and 0.36 in Denmark, and therefore much lower than in Australia where 
rosiglitazone peaked at about 2 DDDs per 1000 insurees. The FDA’s safety warning 
for increased risk of heart failure for all TZDs in August 2007 did not affect pre-
scription growth rates for pioglitazone in Germany or Denmark. However, pioglita-
zone prescriptions declined after the FDA’s and EMA’s safety warning for possibly 
increased risk of bladder cancer for pioglitazone patients in June and July 2011 in 
both countries. ConClusions: TZD prescriptions in Germany and Denmark did not 
decline as radically after the publication of safety warnings as in other countries. 
Differences in reaction speed may reflect different levels of market penetration prior 
to the drug safety warnings and differences in the intensity of the safety warning 
issued by the drug administration authority.
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objeCtives: Type 2 Diabetes is on the rise in many Asian countries with growing 
economic prosperity. Treatment patterns of diabetic patients in South East Asia have 
rarely been studied using administrative data. Our objective was to understand med-
ication use patterns among Malaysian patients with diabetes with comorbidities in 
the primary health care setting. This may be useful for understanding treatment 
strategies in subgroups of patients with diabetes who tend to pose more complex 
challenges in clinical decision-making. Methods: Data was obtained from diabetic 
patients who were audited in the NDR in 2012. Descriptive analysis was used to 
describe medication usage for patients with various comorbidities. Medications of 
interest were antiplatelet medications, lipid-lowering agents, anti-hypertensive and 
various classes of anti-diabetic medications including insulin. Results: A total of 
130,270 patients were identified with comorbidities. Mean age of patients was 59.8 
years old and 60.2% were female. A majority of patients were hypertensive (70.3%), 
more than half were dyslipidemic (55.1%). Other comorbidities such as retinopathy, 
ischemic heart disease (IHD), cerebrovascular disease, nephropathy, diabetic foot 
ulcer, amputation, hypertension and dyslipidemia were recorded among less than 
10% of patients. Among non-diabetes medications, statins was the most commonly 
used ranging from 64.6% to 86.3% for various comorbidities. This was followed by 
ACE-inhibitors and aspirin. Among anti-diabetic medications, metformin was the 
most commonly prescribed followed by sulfonylureas and insulins. ConClusions: 
The registry data was able to shed light on patterns of medication usage among 
diabetic patients with comorbidities. Perhaps in the future, this data can be used 
to evaluate long-term outcomes among patients on various treatment plans and 
finally to inform more evidence-based clinical management strategies relating to 
medication use.
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objeCtives: The objective was to analyze evolving consumption, public costs as 
well as prescription practice pattern of the newer anti-diabetic drugs interfering 
with incretin system, i. e. DPP-IV inhibitors (“gliptins”) and GLP-1 mimetics, and 
compare it to other drugs in the anti-diabetic portfolio. Methods: The phar-
macy claims-based database of the General Health Insurance Company of the 
Czech Republic (VZP CR) was used as the data source. An insured person with a 
recorded prescription for any of the drugs of interest (ATC3 classification A10B: 
blood glucose-lowering drugs excl. insulins) between 2008 and 2013 was defined as 
a patient. Information on pricing and reimbursement were obtained from the files 
of administrative proceedings at the State Institute for Drug Control. Results: 
Since the introduction of sitagliptin in autumn 2008 its utilization rose to 2.1 DDD/
TID in 2013, which makes it the most prescribed incretin-based drug. Overall con-
sumption of all incretin-based therapies was 5.4 DDD/TID in 2013 and the patient 
number represents 9 % of all patients taking any anti-diabetic drug of the ATC A10B 
group (except for insulins). However, in terms of public costs incretin-based agents 
represent already 55% of all the blood glucose-lowering therapy of the evaluated 
A10B group (insulines excluded). In comparison, the utilization of the 1st line drug 
metformin between 2008 and 2013 has been annually rising by 5 % to 10 %, while in 
